We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > I-Mab Biopharma

News List

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs Wuxi Biologics
September 27, 2018
WuXi Biologics and I-Mab Biopharma jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies.
I-Mab Biopharma, MorphoSys declares China IND Submission of monoclonal antibody biospectrumasia
August 10, 2018
The company has Submitted an investigational new drug (IND) application to China National Drug Administration (CNDA) for TJ202/MOR202, a human monoclonal antibody directed against CD38 for the treatment of multiple myeloma.
I-Mab Biopharma, ABL Bio collaborate for innovative bispecific Abs biospectrumasia
July 30, 2018
Under the terms of the agreement, ABL Bio will pay $2.5 million in upfront payment.

Previous page 1 2 Next page